|
|
SPOT ON
|
|
Oseltamivir (TAMIFLU): benefit of the neuraminidase inhibitor remains unclear
|
|
|
NEW ON THE MARKET
|
|
Dexamfetamine (ATTENTIN) for attention deficit hyperactivity disorder?
Azilsartan (EDABRI) - angiotensin II receptor blocker no. 8
|
|
|
a-t READER'S QUESTIONS AND COMMENTS
|
|
Perioperative management of patients with coronary heart disease taking acetylsalicylic acid
Does anticoagulation for atrial fibrillation protect against myocardial infarction?
Do sulfonylureas increase mortality?
What´s new on SINUPRET?
|
|
|
IN BRIEF
|
|
Placebo refused - how independent research is thwarted
|
|
|
CURRENT ADR NETWORK REPORT
|
|
Cancer due to liraglutide (VICTOZA)?
|
|
|
SIDE EFFECTS
|
|
Update: progressive leukoencephalopathy due to natalizumab (TYSABRI)
Consequences of deaths with multiple sclerosis drug fingolimod (GILENYA)
|
|